Limits of [18F]-FLT PET as a Biomarker of Proliferation in Oncology

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  McKinley, Eliot T ^a,b   Ayers, Gregory D ^c   Smith, R Adam ^a   Saleh, Samir A ^a   Zhao, Ping ^a   Washington, Mary Kay ^c,d,e   Coffey, Robert J ^d,e   Manning, H Charles ^a,b,c,d,e  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; BIOLOGICAL MARKER; CYCLINE; KI 67 ANTIGEN; THYMIDINE KINASE 1; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; THYMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT; ANIMAL; CELL STRAIN HCT116; DISEASE MODEL; GENETICS; METABOLISM; MUTATION; NEOPLASM; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MUTATION; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; THYMIDINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875031311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058938     Document Type: Article

References (42)

1. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, et al. (1998) Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39: 1757-1762.
2. Shields AF, Mankoff D, Graham MM, Zheng M, Kozawa SM, et al. (1996) Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med 37: 290-296.
3. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H, (1997) Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 38: 280-287.
4. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, et al. (2003) 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63: 3791-3798.
5. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, et al. (2005) Imaging proliferation in brain tumors with F-18-FLT PET: Comparison with F-18-FDG. Journal of Nuclear Medicine 46: 945-952.
6. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, et al. (2005) [F-18]3 '-deoxy-3 '-fluorothymidine PET for the diagnosis and grading of brain tumors. European Journal of Nuclear Medicine and Molecular Imaging 32: 653-659.
7. Cobben DCP, Elsinga PH, van Waarde A, Jager PL, (2003) Correspondence re: H. Barthel et al., 3 '-deoxy-3 '-[F-18]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res., 63: 3791-3798,2003. Cancer Research 63: 8558-8559.
8. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336.
9. Arner ES, Eriksson S, (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67: 155-186.
10. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, et al. (2007) Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 13: 3460-3469.
11. Grierson JR, Shields AF, (2000) Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27: 143-156.
12. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA, (2004) Metabolism of 3 '-deoxy-3 '-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nuclear Medicine and Biology 31: 829-837.
13. Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, et al. (2006) Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. J Nucl Med 47: 1612-1621.
14. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA, (2003) Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 44: 2027-2032.
15. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, et al. (2003) 3 '-[F-18]fluoro-3 '-deoxythymidine ([F-18]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Research 63: 2681-2687.
16. Brockenbrough JS, Souquet T, Morihara JK, Stern JE, Hawes SE,et al. Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors. J Nucl Med 52: 1181-1188.
17. Olive M, Untawale S, Coffey RJ, Siciliano MJ, Wildrick DM, et al. (1993) Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient. In Vitro Cell Dev Biol 29A: 239-248.
18. Waldman T, Kinzler KW, Vogelstein B, (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190.
19. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
20. Dy DY, Whitehead RH, Morris DL, (1992) SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res 52: 917-923.
21. Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, et al. (2008) Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 14: 7413-7422.
22. Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, et al. (2009) Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15: 4712-4721.
23. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, et al. (2005) Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 46: 371-380.
24. Muzic RF Jr, Cornelius S, (2001) COMKAT: compartment model kinetic analysis tool. J Nucl Med 42: 636-645.
25. Li W, Araya M, Elliott M, Kang X, Gerk PM,et al. Monitoring cellular accumulation of 3'-deoxy-3'-fluorothymidine (FLT) and its monophosphate metabolite (FLT-MP) by LC-MS/MS as a measure of cell proliferation in vitro. J Chromatogr B Analyt Technol Biomed Life Sci 879: 2963-2970.
26. Efron B, Tibshirani R (1993) An Introduction to the Bootstrap. Washington, D.C.: CRC Press.
27. Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL,et al. [18F]FLT-PET imaging does not always "light up" proliferating tumor cells. Clin Cancer Res.
28. Kim SJ, Lee JS, Im KC, Kim SY, Park SA, et al. (2008) Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice. J Nucl Med 49: 2057-2066.
29. Wang H, Zhang J, Tian J, Qu B, Li T, et al. (2009) Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. J Nucl Med 50: 1857-1864.
30. Krieger-Hinck N, Gustke H, Valentiner U, Mikecz P, Buchert R, et al. (2006) Visualisation of neuroblastoma growth in a Scid mouse model using [18F]FDG and [18F]FLT-PET. Anticancer Res 26: 3467-3472.
31. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, et al. (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66: 11055-11061.
32. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, et al. (2006) Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 129: 393-401.
33. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, et al. (2003) [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 30: 1407-1412.
34. van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, et al. (2005) Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 46: 400-404.
35. Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, et al. (2002) 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 62: 3331-3334.
36. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, et al. (2007) Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34: 1610-1616.
37. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, et al. (2005) Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65: 10104-10112.
38. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, et al. (2004) PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31: 720-724.
39. Yamamoto Y, Kameyama R, Izuishi K, Takebayashi R, Hagiike M, et al. (2009) Detection of colorectal cancer using (1)F-FLT PET: comparison with (1)F-FDG PET. Nucl Med Commun 30: 841-845.
40. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, et al. (2003) In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52: 1602-1606.
41. McKinley ET, Smith RA, Tanksley JP, Washington MK, Walker R,et al. [(18)F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Menetrier's disease. Ann Nucl Med.
42. Moroz MA, Kochetkov T, Cai S, Wu J, Shamis M,et al. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging. Clin Cancer Res 17: 1099-1110.